CR11737A - Polipéptidos modificados del factor ix y usos de los mismos - Google Patents

Polipéptidos modificados del factor ix y usos de los mismos

Info

Publication number
CR11737A
CR11737A CR11737A CR11737A CR11737A CR 11737 A CR11737 A CR 11737A CR 11737 A CR11737 A CR 11737A CR 11737 A CR11737 A CR 11737A CR 11737 A CR11737 A CR 11737A
Authority
CR
Costa Rica
Prior art keywords
factor
modified
polypeptides
polipeptides
same
Prior art date
Application number
CR11737A
Other languages
English (en)
Inventor
Alan Brooks
John E Murphy
Marian Seto
Xiaoqiao Jian
Chandra Patel
Uwe Gritzan
Kornelia Kirchner
Ulrich Haupts
Original Assignee
Bayer Schering Pharma Ag
Bayer Healthcare Llc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Bayer Healthcare Llc, Schering Corp filed Critical Bayer Schering Pharma Ag
Publication of CR11737A publication Critical patent/CR11737A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se divulgan polipéptidos modificados del factor IX, tales como los polipéptidos del factor IX con uno o más sitios de glicosilación introducidos. Los polipéptidos modificados del factor IX pueden exhibir un incremento de la estabilidad in vitro o in vivo, tal como una semivida plasmática más prolongada. Asimismo se divulgan procedimientos de fabricar polipéptidos modificados del factor IX y a procedimientos de usar modificados del factor IX para, por ejemplo, tratar a pacientes afectados por hemofilia B.
CR11737A 2008-04-16 2010-10-15 Polipéptidos modificados del factor ix y usos de los mismos CR11737A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US4596108P 2008-04-17 2008-04-17

Publications (1)

Publication Number Publication Date
CR11737A true CR11737A (es) 2011-02-07

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11737A CR11737A (es) 2008-04-16 2010-10-15 Polipéptidos modificados del factor ix y usos de los mismos

Country Status (17)

Country Link
EP (1) EP2288622A4 (es)
JP (1) JP2011517951A (es)
KR (1) KR20110005862A (es)
CN (1) CN102083856A (es)
AU (1) AU2009244633A1 (es)
BR (1) BRPI0910702A2 (es)
CA (1) CA2721683A1 (es)
CO (1) CO6311000A2 (es)
CR (1) CR11737A (es)
DO (1) DOP2010000311A (es)
EC (1) ECSP10010551A (es)
IL (1) IL208718A0 (es)
MX (1) MX2010011345A (es)
RU (1) RU2010146387A (es)
SG (1) SG189790A1 (es)
SV (1) SV2010003704A (es)
WO (1) WO2009137254A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383388B2 (en) * 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
CN104004739A (zh) * 2007-10-15 2014-08-27 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ix变体
DK2337849T3 (en) * 2008-09-15 2018-10-01 Uniqure Biopharma B V FACTOR IX POLYPEPTIME MUTANT, APPLICATIONS THEREOF AND METHOD OF PRODUCING THEREOF
KR20230156435A (ko) 2010-07-09 2023-11-14 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
TWI595004B (zh) * 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
JP5967631B2 (ja) * 2012-04-27 2016-08-10 学校法人日本大学 上皮及び内皮損傷の治療剤
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
DK3889173T3 (da) 2013-02-15 2023-10-09 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
EP3903599A1 (en) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
US20160289633A1 (en) 2013-12-20 2016-10-06 Biogen Ma Inc. Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
KR102385372B1 (ko) 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
CN105695616A (zh) * 2016-04-22 2016-06-22 王冬国 诊断甲状腺癌的分析标志物及其应用
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
AR110871A1 (es) 2017-01-31 2019-05-08 Bioverativ Therapeutics Inc Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas
FR3069540B1 (fr) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 Proteine modifiee avec demi-vie amelioree
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US20200263196A1 (en) 2017-09-27 2020-08-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
CA3096038A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
KR20220009389A (ko) 2019-04-17 2022-01-24 코디악 바이오사이언시즈, 인크. 엑소좀 및 aav 의 조성물
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
EP4298737A1 (en) 2021-02-24 2024-01-03 BlueHalo LLC System and method for a digitally beamformed phased array feed
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US6531298B2 (en) * 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
CA2457429A1 (en) * 2001-09-04 2003-03-13 Francis J. Carr Modified factor ix
CA2520970A1 (en) * 2003-04-09 2004-10-28 Robert G. Schaub Hemophilia treatment by inhalation of coagulation factors
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP4738346B2 (ja) * 2003-12-03 2011-08-03 ノヴォ ノルディスク アー／エス ＧｌｙｃｏＰＥＧ化された第ＩＸ因子
US8383388B2 (en) * 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
AU2009244633A1 (en) 2009-11-12
RU2010146387A (ru) 2012-05-27
CN102083856A (zh) 2011-06-01
BRPI0910702A2 (pt) 2016-07-05
IL208718A0 (en) 2010-12-30
EP2288622A2 (en) 2011-03-02
SV2010003704A (es) 2011-02-21
ECSP10010551A (es) 2010-11-30
KR20110005862A (ko) 2011-01-19
SG189790A1 (en) 2013-05-31
CO6311000A2 (es) 2011-08-22
WO2009137254A3 (en) 2010-01-14
WO2009137254A2 (en) 2009-11-12
CA2721683A1 (en) 2009-11-12
MX2010011345A (es) 2011-02-23
DOP2010000311A (es) 2011-02-28
JP2011517951A (ja) 2011-06-23
EP2288622A4 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
CR11737A (es) Polipéptidos modificados del factor ix y usos de los mismos
CR20120052A (es) Polipéptidos del factor ix modificados y usos de los mismos
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
IN2014DN09782A (es)
CO6331368A2 (es) Factores modificados de polipeptidos vii (fvii)
CR20120273A (es) OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO MODULADORES DEL RECEPTOR DE OREXINA
SV2009003393A (es) Polipeptidos de factor vii modificaciones y usos de los mismos
AR084057A1 (es) Composiciones para el cuidado de telas
WO2012106281A3 (en) Multimodal trail molecules and uses in cellular therapies
IN2014DN06191A (es)
BR112014012524A2 (pt) composições compreendendo um componente de estabilidade do prazo de validade
CR20110630A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
CR11866A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
UY32445A (es) Composicion y procedimiento para usar aminopiridinas
DK2252322T3 (da) Vaccinesammensætninger
IN2014DN06104A (es)
UY29361A1 (es) Pirroles e imidazoles sustituídos, composiciones que los contienen, procedimiento de fabricación y utilización
DOP2009000264A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
DOP2010000251A (es) Paramyxovirus eficaz como antitumoral
MX353641B (es) Composiciones colorantes para el cabello con un agente alcalinizante sin amoniaco.
MX2012001409A (es) Fragmento de agrina modificado capaz de restaurar la potencia muscular para utilizarse como un medicamento.
BR112014016803A8 (pt) amidas macrocíclicas como inibidoras de protease
ECSP13012613A (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
MX349583B (es) Composiciones azeotrópicas de 1, 1, 3, 3 - tetracloro - 1 - fluoropropano y fluoruro de hidrógeno.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)